All manuscripts
Publications Other

Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry

Published

Share
26 pages Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry

Overview

This guidance provides recommendations for developing a science- and risk-based strategy to help assure the potency of a human cellular therapy or gene therapy (CGT) product. This final guidance supersedes the document entitled “Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products,” dated January 2011.

What this paper found

FDA's final guidance on potency assurance for cellular and gene therapy products, issued in November 2026, asks manufacturers to assure potency through a science- and risk-based strategy rather than through release testing alone. It supersedes the January 2011 guidance on potency tests. The strategy combines manufacturing process design, process and material controls, in-process testing and lot release assays, grounded in quality risk management across the product lifecycle. For most products, lot release should feature one or more bioassays suited to the development phase. Potency release assays should be qualified no later than the start of trials meant to provide substantial evidence of effectiveness, and must be validated for licensed products. Acceptance criteria should be quantitative: "report" or "for information only" is not recommended. The guidance is nonbinding.

Study details

Authors
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research
Institution
Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services
Year
2026
Cell type(s)
Other

Explore related

Full citation

U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry. November 2026.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →